BCL2 and lymphoma: Because CD115 marks more specialized monocytic cells than the pan-myeloid marker CD11b, we focused on the CD115-positive subpopulation of TIS control;bcl2 lymphomas, which we hypothesized to reflect a more advanced stage in the B-to-M transition compared to the CD115– fraction (Supplementary Fig. 4a).